1. Home
  2. MDXH vs FCO Comparison

MDXH vs FCO Comparison

Compare MDXH & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDXH
  • FCO
  • Stock Information
  • Founded
  • MDXH 2003
  • FCO 1991
  • Country
  • MDXH Belgium
  • FCO United Kingdom
  • Employees
  • MDXH N/A
  • FCO N/A
  • Industry
  • MDXH
  • FCO Investment Managers
  • Sector
  • MDXH
  • FCO Finance
  • Exchange
  • MDXH Nasdaq
  • FCO Nasdaq
  • Market Cap
  • MDXH 84.6M
  • FCO 78.3M
  • IPO Year
  • MDXH 2021
  • FCO N/A
  • Fundamental
  • Price
  • MDXH $2.09
  • FCO $6.33
  • Analyst Decision
  • MDXH Buy
  • FCO
  • Analyst Count
  • MDXH 1
  • FCO 0
  • Target Price
  • MDXH $6.00
  • FCO N/A
  • AVG Volume (30 Days)
  • MDXH 75.5K
  • FCO 100.1K
  • Earning Date
  • MDXH 05-14-2025
  • FCO 01-01-0001
  • Dividend Yield
  • MDXH N/A
  • FCO 14.96%
  • EPS Growth
  • MDXH N/A
  • FCO N/A
  • EPS
  • MDXH N/A
  • FCO 0.43
  • Revenue
  • MDXH $94,507,000.00
  • FCO N/A
  • Revenue This Year
  • MDXH $23.38
  • FCO N/A
  • Revenue Next Year
  • MDXH $16.84
  • FCO N/A
  • P/E Ratio
  • MDXH N/A
  • FCO $12.30
  • Revenue Growth
  • MDXH 25.46
  • FCO N/A
  • 52 Week Low
  • MDXH $1.35
  • FCO $4.73
  • 52 Week High
  • MDXH $3.50
  • FCO $6.63
  • Technical
  • Relative Strength Index (RSI)
  • MDXH 74.52
  • FCO 67.87
  • Support Level
  • MDXH $1.67
  • FCO $6.08
  • Resistance Level
  • MDXH $1.99
  • FCO $6.33
  • Average True Range (ATR)
  • MDXH 0.13
  • FCO 0.14
  • MACD
  • MDXH 0.02
  • FCO 0.03
  • Stochastic Oscillator
  • MDXH 97.67
  • FCO 95.56

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

About FCO abrdn Global Income Fund Inc.

abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.

Share on Social Networks: